OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Brinter has successfully closed a €1.2 million (US $1.5 million) seed funding round, which was led by the early-stage venture capitalist Innovestor.
Bioprinting start-up company, Brinter, has successfully closed a €1.2 million (US $1.5 million) seed funding round, which was led by the early-stage venture capitalist Innovestor. The financing announcement was made in a June 10, 2021 press release.
The monies raised will be used by Brinter to expand operations internationally in Europe and the United States. The company’s modular multi-material 3D bioprinting solution offers a scalable approach to shorten and enhance the productivity of the scientific process and bio-manufacturing.
“We are excited to have the backing of Innovestor who can help us accelerate the development of our operational capabilities and scale in new geographies,” said Brinter CEO Tomi Kalpio, in the press release. “Bioprinting has the capability to rapidly unlock the opportunities behind long-running but unrealized science and research, and plays a key role in pushing the frontier of medical science. This will result in an improved quality of life for patients through the expansion of more personalized treatment and the ongoing development of bioprinted ‘spare parts’ that can save lives.”
“Brinter is an exciting addition to our portfolio as it not only fits in our focus areas of industrial and health technologies, but the company’s competitive advantages of multi-material printing capabilities, modularity, and scalability combined with their own easy-to-use software application were very convincing,” added Wilhelm Lindholm, CEO of Innovestor, in the press release.